Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04753320 · ClinicalTrials.gov registry record
Remote Monitoring in Progressive Supranuclear Palsy (PSP)
A clinical trial of Parkinson Disease and Progressive Supranuclear Palsy, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- 85
- Enrollment target
- 2
- Study locations
NCT04753320: Active study of Parkinson Disease and Progressive Supranuclear Palsy, sponsored by Massachusetts General Hospital.
NCT04753320 is a study of Parkinson Disease and Progressive Supranuclear Palsy that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 85 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04753320, a study of Parkinson Disease and Progressive Supranuclear Palsy, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 85 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a single-arm, longitudinal, observational study on the use of wearable sensors and digital health technology to measure fall frequency and motor, speech, and cognitive function in patients with PSP over the course of approximately one year. Participants will perform supervised remote assessments monthly and in-person assessments approximately every 6 months.
Primary Outcome
Compliance will be calculated as the number of participants who wear their PAMSys pendant sensors at least 16 hours/day for at least 180 days and complete at least 80% of their scheduled monthly sensor and tablet derived motor, speech, and cognitive assessments through their 6 month visit.
Conditions Studied
Study Locations (2)
Maryland
- Johns Hopkins - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2021-05-05 |
| Est. Completion | 2026-12 |
What the registry record for NCT04753320 still lists
NCT04753320 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 0 interventions.
NCT04753320 reports a single indexed study location in Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04753320 about?
NCT04753320 is a clinical study titled "Remote Monitoring in Progressive Supranuclear Palsy (PSP)". This is a single-arm, longitudinal, observational study on the use of wearable sensors and digital health technology to measure fall frequency and motor, speech, and cognitive function in patients with PSP over the course of approximately one year. Participants will perform supervised remote assessm...
What is the current status of trial NCT04753320?
This trial is currently active not recruiting. The enrollment target is 85 participants. The study started on 2021-05-05. Estimated completion is 2026-12.
What conditions does trial NCT04753320 study?
This clinical trial studies the following conditions: Parkinson Disease, Progressive Supranuclear Palsy, MSA - Multiple System Atrophy.
Who is sponsoring clinical trial NCT04753320?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04753320 being conducted?
This trial has 2 study locations across Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04753320's enrollment target sits among peer trials
85 101st of 297 higher than 197 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI